ArticleArthritis research & therapy2026
Incidence and spectrum of primary respiratory disease throughout the course of rheumatoid arthritis: implications of structured repeated evaluation for detection and risk-factor analysis.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the incidence and spectrum of lung involvement in early RA through a structured respiratory assessment and to identify its clinical predictors.
methodsA retrospective study was conducted in a cohort of 204 early RA patients screened for lung involvement at RA onset and during follow-up. Cumulative incidence (CI) at four and eight years, incidence rate (IR), and frequency were calculated for the different manifestations identified. Cox regression was used to assess potential risk factors.
resultsPulmonary involvement was identified in 89 of 204 patients (43.6%). The CI increased from 17.5% at four years to 25.2% at eight years. The IR was 42.0 per 1,000 person-years among patients without prior lung disease, rising to 50.2 when including pre-existing cases. The screening strategy proved effective, detecting asymptomatic lung involvement in one-quarter of patients (51/204). Interstitial lung disease (ILD) (22.5%) and bronchiectasis (22.1%) were the most frequent manifestations, followed by follicular bronchiolitis (FB) (7.8%), pulmonary nodules (5.4%), pleural disease (3.4%), and obliterative bronchiolitis (OB) (1%). The IRs were 20.4 for bronchiectasis, 16.2 for ILD, 6.9 for FB, 4.9 for nodules, 2.0 for pleural disease, and 1.0 for OB. Bronchiectasis showed the highest CI (8.8% at four years and 12.9% at eight years), followed by ILD (7.5% and 11.6%). Age at RA onset (≥ 60 years) was independently associated with overall lung involvement (HR 2.22, 95% CI 1.20–4.11), ILD (HR 3.36, 95% CI 1.23–9.20), and bronchiectasis (HR 2.42, 95% CI 1.07–5.43). Male sex was associated with ILD (HR 5.11, 95% CI 1.52–17.13).
conclusionsProactive screening identified a high incidence of ILD and airway disease in early RA, supporting routine pulmonary evaluation to attempt to optimise early detection and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.